Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TOKYO, May 31, 2024 (GLOBE NEWSWIRE) -- Earlyworks Co., Ltd. (Nasdaq: ELWS) (the “Company” or “Earlyworks”) (Head office: Taito-ku, Tokyo; CEO: Satoshi Kobayashi), a blockchain solution provider...
-
Aðalfundur Ölgerðarinnar var haldinn 23. maí 2024 í höfuðstöðvum félagsins að Grjóthálsi 7-11, 110 Reykjavík. Meðfylgjandi eru helstu niðurstöður fundarins. Viðhengi ...
-
TOKYO, May 21, 2024 (GLOBE NEWSWIRE) -- Earlyworks Co., Ltd. (Nasdaq: ELWS) (the “Company” or “Earlyworks”) (Head office: Taito-ku, Tokyo; CEO: Satoshi Kobayashi), a blockchain solution provider...
-
Aðalfundur Ölgerðarinnar Egill Skallagrímsson hf. verður haldinn fimmtudaginn 23. maí 2024, kl. 16:00, í höfuðstöðvum félagsins að Grjóthálsi 7-11 í Reykjavík. Framboðsfrestur til stjórnar rann...
-
A total of 9,817 hotels or 955,657 hotel rooms in operation as of March 31, 2024.Hotel turnover1 increased 21.1% year-over-year to RMB19.7 billion in the first quarter of 2024. Excluding Steigenberger...
-
Multitude Group publishes restated interim results for 2023 due to prior period adjustments and changes in presentation Helsinki, 15 May 2024 – Multitude SE, a listed European FinTech company,...
-
Amounts in US$ unless otherwise noted Record quarterly net revenue of US$262.5 million driving record adjusted EPS of US$0.27 and adjusted free cash flow per share of US$0.35Solid net revenue growth...
-
Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024;...
-
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- --...
-
- Data show that AXV-101 halts photoreceptor and outer nuclear retinal layer (ONL) degeneration in a dose-dependent manner - - Company to initiate clinical studies in 1H 2025 to treat blindness and...